PURPOSE: The objectives of this study were to investigate the predictive value of tumour measurements on 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) positron emission tomography (PET) pretreatment scan regarding therapy response in oesophageal cancer and to evaluate the impact of tumour delineation strategies. METHODS: Fifty patients with oesophageal cancer treated with concomitant radiochemotherapy between 2004 and 2008 were retrospectively considered and classified as complete, partial or non-responders (including stable and progressive disease) according to Response Evaluation Criteria in Solid Tumors (RECIST). The classification of partial and complete responders was confirmed by biopsy. Tumours were delineated on the (18)F-FDG pretreatment scan using an adaptive threshold and the automatic fuzzy locally adaptive Bayesian (FLAB) methodologies. Several parameters were then extracted: maximum and peak standardized uptake value (SUV), tumour longitudinal length (TL) and volume (TV), SUV(mean), and total lesion glycolysis (TLG = TV × SUV(mean)). The correlation between each parameter and response was investigated using Kruskal-Wallis tests, and receiver-operating characteristic methodology was used to assess performance of the parameters to differentiate patients. RESULTS: Whereas commonly used parameters such as SUV measurements were not significant predictive factors of the response, parameters related to tumour functional spatial extent (TL, TV, TLG) allowed significant differentiation of all three groups of patients, independently of the delineation strategy, and could identify complete and non-responders with sensitivity above 75% and specificity above 85%. A systematic although not statistically significant trend was observed regarding the hierarchy of the delineation methodologies and the parameters considered, with slightly higher predictive value obtained with FLAB over adaptive thresholding, and TLG over TV and TL. CONCLUSION: TLG is a promising predictive factor of concomitant radiochemotherapy response with statistically higher predictive value than SUV measurements in advanced oesophageal cancer.
PURPOSE: The objectives of this study were to investigate the predictive value of tumour measurements on 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) positron emission tomography (PET) pretreatment scan regarding therapy response in oesophageal cancer and to evaluate the impact of tumour delineation strategies. METHODS: Fifty patients with oesophageal cancer treated with concomitant radiochemotherapy between 2004 and 2008 were retrospectively considered and classified as complete, partial or non-responders (including stable and progressive disease) according to Response Evaluation Criteria in Solid Tumors (RECIST). The classification of partial and complete responders was confirmed by biopsy. Tumours were delineated on the (18)F-FDG pretreatment scan using an adaptive threshold and the automatic fuzzy locally adaptive Bayesian (FLAB) methodologies. Several parameters were then extracted: maximum and peak standardized uptake value (SUV), tumour longitudinal length (TL) and volume (TV), SUV(mean), and total lesion glycolysis (TLG = TV × SUV(mean)). The correlation between each parameter and response was investigated using Kruskal-Wallis tests, and receiver-operating characteristic methodology was used to assess performance of the parameters to differentiate patients. RESULTS: Whereas commonly used parameters such as SUV measurements were not significant predictive factors of the response, parameters related to tumour functional spatial extent (TL, TV, TLG) allowed significant differentiation of all three groups of patients, independently of the delineation strategy, and could identify complete and non-responders with sensitivity above 75% and specificity above 85%. A systematic although not statistically significant trend was observed regarding the hierarchy of the delineation methodologies and the parameters considered, with slightly higher predictive value obtained with FLAB over adaptive thresholding, and TLG over TV and TL. CONCLUSION:TLG is a promising predictive factor of concomitant radiochemotherapy response with statistically higher predictive value than SUV measurements in advanced oesophageal cancer.
Authors: H L van Westreenen; M Westerterp; P M M Bossuyt; J Pruim; G W Sloof; J J B van Lanschot; H Groen; J Th M Plukker Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544
Authors: Johannes B Roedl; Mukesh G Harisinghani; Rivka R Colen; Alan J Fischman; Michael A Blake; Douglas J Mathisen; Peter R Mueller Journal: Ann Thorac Surg Date: 2008-10 Impact factor: 4.330
Authors: Steven M. Larson; Yusuf Erdi; Timothy Akhurst; Madhu Mazumdar; Homer A. Macapinlac; Ronald D. Finn; Cecille Casilla; Melissa Fazzari; Neil Srivastava; Henry W.D. Yeung; John L. Humm; Jose Guillem; Robert Downey; Martin Karpeh; Alfred E. Cohen; Robert Ginsberg Journal: Clin Positron Imaging Date: 1999-05
Authors: Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake Journal: Radiother Oncol Date: 2008-08-11 Impact factor: 6.280
Authors: Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim Journal: Ann Surg Oncol Date: 2009-10-14 Impact factor: 5.344
Authors: David P Kelsen; Katryn A Winter; Leonard L Gunderson; Joanne Mortimer; Norman C Estes; Daniel G Haller; Jaffer A Ajani; Walter Kocha; Bruce D Minsky; Jack A Roth; Christopher G Willett Journal: J Clin Oncol Date: 2007-08-20 Impact factor: 44.544
Authors: Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera Journal: Eur J Nucl Med Mol Imaging Date: 2015-02-14 Impact factor: 9.236
Authors: Ho Seong Kim; Joon Young Choi; Dong Wook Choi; Ho Yeong Lim; Joo Hee Lee; Sun Pyo Hong; Young Seok Cho; Kyung-Han Lee; Byung-Tae Kim Journal: Nucl Med Mol Imaging Date: 2014-02-07
Authors: Charles Lemarignier; Frédéric Di Fiore; Charline Marre; Sébastien Hapdey; Romain Modzelewski; Pierrick Gouel; Pierre Michel; Bernard Dubray; Pierre Vera Journal: Eur J Nucl Med Mol Imaging Date: 2014-07-19 Impact factor: 9.236